Regulatory B cells (Bregs) have been shown to play a role in inflammatory bowel disease (IBD) in humans, as B cell depletion in patients with IBD tends to aggravate the disease. Furthermore it has been demonstrated that co-transfer of eAg-exposed B cells improves symptoms of experimental colitis in the T cell transfer model of colitis. […]
| Inventor | Institute |
|---|---|
| Anders Elm Pedersen ; Mogens H Claesson | University of Copenhagen |
| Cat. #: | 153819 |
|---|---|
| Unit size: | 100 ug |
| Research Fields: | Other |
| Target: | Enteroantigen |
| Clone: | F8 |
| Class: | Monoclonal |
| Product description: | Regulatory B cells (Bregs) have been shown to play a role in inflammatory bowel disease (IBD) in humans, as B cell depletion in patients with IBD tends to aggravate the disease. Furthermore it has been demonstrated that co-transfer of eAg-exposed B cells improves symptoms of experimental colitis in the T cell transfer model of colitis. This eAg-specific B cell hybridoma offers a unique tool to investigate the immune response towards eAgÄËĂÂĂÂs in experimental colitis, and potentially,… |
|---|---|
| Conjugation: | Unconjugated |
| Target background: | Regulatory B cells (Bregs) have been shown to play a role in inflammatory bowel disease (IBD) in humans, as B cell depletion in patients with IBD tends to aggravate the disease. Furthermore it has been demonstrated that co-transfer of eAg-exposed B cells improves symptoms of experimental colitis in the T cell transfer model of colitis. This eAg-specific B cell hybridoma offers a unique tool to investigate the immune response towards eAgÄËĂÂĂÂs in experimental colitis, and potentially,… |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 0.9-1.1mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | -15° C to -25° C |
| Shipping conditions: | Dry ice |
| References: |
In vitro cloning and regulatory potential of B cell hybridomas secreting entero-antigen specific antibody. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151023 | Anti-IL12 [1-1D5] |
Key Info
Anti-IL12 [1-1D5]
|
View Tool | |||||||||||||||||||
| 151031 | Anti-RuvA [RuvA 12C6] |
Key Info
Anti-RuvA [RuvA 12C6]
|
View Tool | |||||||||||||||||||
| 151037 | Anti-Cdk1 [17 (A17)] |
Key Info
Anti-Cdk1 [17 (A17)]
|
View Tool | |||||||||||||||||||
| 151039 | Anti-Integrin aVb3 [23C6] |
Key Info
Anti-Integrin aVb3 [23C6]
|
View Tool | |||||||||||||||||||
| 151018 | Anti-Mos [R38.1] |
Key Info
Anti-Mos [R38.1]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.